Literature DB >> 18319312

Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder.

Evangelia Charmandari1, Tomoshige Kino, Takamasa Ichijo, George P Chrousos.   

Abstract

CONTEXT: Primary generalized glucocorticoid resistance is a rare genetic condition characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. We review the clinical aspects, molecular mechanisms, and implications of this disorder. EVIDENCE ACQUISITION: We conducted a systematic review of the published, peer-reviewed medical literature using MEDLINE (1975 through February 2008) to identify original articles and reviews on this topic. EVIDENCE SYNTHESIS: We have relied on the experience of a number of experts in the field, including our extensive personal experience.
CONCLUSIONS: The clinical spectrum of primary generalized glucocorticoid resistance is broad, ranging from asymptomatic to severe cases of hyperandrogenism, fatigue, and/or mineralocorticoid excess. The molecular basis of the condition has been ascribed to mutations in the human glucocorticoid receptor (hGR) gene, which impair glucocorticoid signal transduction and reduce tissue sensitivity to glucocorticoids. A consequent increase in the activity of the hypothalamic-pituitary-adrenal axis compensates for the reduced sensitivity of peripheral tissues to glucocorticoids at the expense of ACTH hypersecretion-related pathology. The study of functional defects of natural hGR mutants enhances our understanding of the molecular mechanisms of hGR action and highlights the importance of integrated cellular and molecular signaling mechanisms for maintaining homeostasis and preserving normal physiology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319312      PMCID: PMC2386273          DOI: 10.1210/jc.2008-0040

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  68 in total

1.  Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells.

Authors:  Jerome Galon; Denis Franchimont; Naoki Hiroi; Gregory Frey; Antje Boettner; Monika Ehrhart-Bornstein; John J O'Shea; George P Chrousos; Stefan R Bornstein
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

2.  Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene.

Authors:  Berenice B Mendonca; Maristela V Leite; Margaret de Castro; Tomoshige Kino; Lucila L K Elias; Tania A S Bachega; Ivo J P Arnhold; George P Chrousos; Ana Claudia Latronico
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 3.  Combinatorial control of gene expression by nuclear receptors and coregulators.

Authors:  Neil J McKenna; Bert W O'Malley
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

Review 4.  Binding of ligands and activation of transcription by nuclear receptors.

Authors:  A C Steinmetz; J P Renaud; D Moras
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

Review 5.  Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes.

Authors:  T Kino; G P Chrousos
Journal:  J Endocrinol       Date:  2001-06       Impact factor: 4.286

Review 6.  Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport.

Authors:  Laura J Terry; Eric B Shows; Susan R Wente
Journal:  Science       Date:  2007-11-30       Impact factor: 47.728

7.  DNA binding domains in diverse nuclear receptors function as nuclear export signals.

Authors:  B E Black; J M Holaska; F Rastinejad; B M Paschal
Journal:  Curr Biol       Date:  2001-11-13       Impact factor: 10.834

8.  Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis.

Authors:  Y Tao; C Williams-Skipp; R I Scheinman
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

9.  Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene.

Authors:  N A Huizenga; P de Lange; J W Koper; W W de Herder; R Abs; J H Kasteren; F H de Jong; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

10.  Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking.

Authors:  T Kino; R H Stauber; J H Resau; G N Pavlakis; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

View more
  41 in total

Review 1.  Anti-inflammatory glucocorticoid drugs: reflections after 60 years.

Authors:  Michael W Whitehouse
Journal:  Inflammopharmacology       Date:  2010-10-31       Impact factor: 4.473

Review 2.  Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes.

Authors:  Evangelia Charmandari; Tomoshige Kino
Journal:  Eur J Clin Invest       Date:  2010-08-19       Impact factor: 4.686

3.  A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.

Authors:  Nancy Nader; Bert E Bachrach; Darrell E Hurt; Sonia Gajula; Amy Pittman; Rachel Lescher; Tomoshige Kino
Journal:  J Clin Endocrinol Metab       Date:  2010-03-24       Impact factor: 5.958

Review 4.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

Review 5.  Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders.

Authors:  George P Chrousos; Tomoshige Kino
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 6.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

7.  Dosing of glucocorticosteroids in nephrotic syndrome.

Authors:  Otto Mehls; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2011-09-09       Impact factor: 3.714

8.  A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD.

Authors:  Michael L Roberts; Tomoshige Kino; Nicolas C Nicolaides; Darrell E Hurt; Eleni Katsantoni; Amalia Sertedaki; Filadelfia Komianou; Korina Kassiou; George P Chrousos; Evangelia Charmandari
Journal:  J Clin Endocrinol Metab       Date:  2013-02-20       Impact factor: 5.958

9.  A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.

Authors:  Nicolas C Nicolaides; Michael L Roberts; Tomoshige Kino; Geoffrey Braatvedt; Darrell E Hurt; Eleni Katsantoni; Amalia Sertedaki; George P Chrousos; Evangelia Charmandari
Journal:  J Clin Endocrinol Metab       Date:  2014-01-31       Impact factor: 5.958

10.  Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  Jérôme Bouligand; Brigitte Delemer; Annie-Claude Hecart; Geri Meduri; Say Viengchareun; Larbi Amazit; Séverine Trabado; Bruno Fève; Anne Guiochon-Mantel; Jacques Young; Marc Lombès
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.